{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:29:21Z","timestamp":1788744561329,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["850450"],"award-info":[{"award-number":["850450"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.lanepe.2023.100737","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T16:57:35Z","timestamp":1698339455000},"page":"100737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-8868","authenticated-orcid":false,"given":"Oriol","family":"Mitj\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Su\u00f1er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Giacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Vall-Mayans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-6952","authenticated-orcid":false,"given":"George-Sorin","family":"Tiplica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.C.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2023.100737_bib1","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib2","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.lanepe.2023.100742","article-title":"Epidemiology and determinants of reemerging bacterial sexually transmitted infections (STIs) and emerging STIs in Europe.","volume":"34","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet Reg Health Eur."},{"key":"10.1016\/j.lanepe.2023.100737_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","author":"Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.lanepe.2023.100737_bib4","series-title":"Gonococcal antimicrobial susceptibility surveillance in the European Union\/summary of results for 2019","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-022-07509-w","article-title":"Significant increase in azithromycin \u201cresistance\u201d and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019","volume":"22","author":"Day","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.lanepe.2023.100737_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.lanepe.2023.100737_bib8","series-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"10.1016\/j.lanepe.2023.100737_bib9","series-title":"British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae (2019)","author":"Fifer","year":"2019"},{"key":"10.1016\/j.lanepe.2023.100737_bib10","series-title":"Australia STI management guidelines gonorrhoea","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib11","series-title":"Sexually transmitted infections treatment guidelines, 2021, gonococcal infections among adolescents and adults","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01644-18","article-title":"Pharmacokinetic data are predictive of in\u00a0vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model","volume":"63","author":"Connolly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2012.176575","article-title":"Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada","volume":"309","author":"Allen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2023.100737_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/sextrans-2014-051730","article-title":"Will use of combination cephalosporin\/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae?","volume":"91","author":"Rice","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib15","series-title":"IUSTI-Europe statement on spectinomycin","author":"Heller-Vitouch","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib16","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial","volume":"393","author":"Ross","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2023.100737_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(21)00625-3","article-title":"Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial","volume":"22","author":"de Vries","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/ciaa596","article-title":"Resistance-guided treatment of gonorrhea: a prospective clinical study","volume":"73","author":"Klausner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4386127","article-title":"A\u00a0systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and trichomonas vaginalis","volume":"2016","author":"Herbst De Cortina","year":"2016","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.lanepe.2023.100737_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, doseranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib22","article-title":"Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections","volume":"13","author":"Jacobsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2023.100737_bib23","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/S2468-2667(17)30051-8","article-title":"eSexual health interventions: promising, but more evidence needed","volume":"2","author":"Wellings","year":"2017","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.lanepe.2023.100737_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000001777","article-title":"A\u00a0systematic review of kissing as a risk factor for oropharyngeal gonorrhoea or chlamydia","author":"Charleson","year":"2023","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/OLQ.0000000000001707","article-title":"An evaluation of digital partner notification tool engagement and impact for patients diagnosed with gonorrhea and syphilis","volume":"49","author":"Folke","year":"2022","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib26","author":"Estcourt"},{"key":"10.1016\/j.lanepe.2023.100737_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/sextrans-2021-055382","article-title":"Non-empirical management of asymptomatic chlamydia and gonorrhoea reduces unnecessary antibiotic use fivefold: a before and after study","volume":"99","author":"Rasul","year":"2023","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2402.170902","article-title":"Use of pristinamycin for Macrolide-Resistant mycoplasma genitalium infection","volume":"24","author":"Read","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa291","article-title":"Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance","volume":"7","author":"Doyle","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02380-17","article-title":"In\u00a0vitro activity of lefamulin against sexually transmitted bacterial pathogens","volume":"62","author":"Paukner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib31","author":"Lefamulin for M"},{"key":"10.1016\/j.lanepe.2023.100737_bib32","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/AAC.02411-14","article-title":"In\u00a0vitro activity of the new fluoroketolide solithromycin (cem-101) against macrolide-resistant and -susceptible mycoplasma genitalium strains","volume":"58","author":"Jensen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jac\/dky022","article-title":"In\u00a0vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains","volume":"73","author":"Dami\u00e3o Gouveia","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib34","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1080\/22221751.2020.1775498","article-title":"In\u00a0vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium","volume":"9","author":"Jensen","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00006-23","article-title":"In\u00a0vitro susceptibility and resistance of Mycoplasma genitalium to nitroimidazoles","volume":"67","author":"Wood","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00698-20","article-title":"In\u00a0vitro activities of eravacycline and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"64","author":"Waites","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03654-22","article-title":"Omadacycline is highly active in\u00a0vitro against Mycoplasma genitalium","volume":"10","author":"Waites","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanepe.2023.100737_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/jdv.17972","article-title":"2021 European guideline on the management of Mycoplasma genitalium infections","volume":"36","author":"Jensen","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.lanepe.2023.100737_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad057","article-title":"gyrA mutations in mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy","author":"Murray","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/cid\/ciu1162","article-title":"Macrolide resistance and azithromycin failure in a mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens","volume":"60","author":"Bissessor","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/0956462419825948","article-title":"British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018)","volume":"30","author":"Soni","year":"2019","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.lanepe.2023.100737_bib43","series-title":"Australian STI Management guideline, Mycoplasma genitalium","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib44","series-title":"Sexually transmitted infections treatment guidelines, 2021","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100737_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ312","article-title":"Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis","volume":"61","author":"Lis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/sextrans-2021-055352","article-title":"Adverse pregnancy and perinatal outcomes associated with Mycoplasma genitalium: systematic review and meta-analysis","volume":"98","author":"Frenzer","year":"2022","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/civ270","article-title":"High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection","volume":"61","author":"Tanizaki","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/sextrans-2020-054823","article-title":"Clinical efficacy and tolerability of 1.5 g\/day oral amoxicillin therapy without probenecid for the treatment of syphilis","volume":"98","author":"Ikeuchi","year":"2022","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib49","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3201\/eid2606.191300","article-title":"Effectiveness and tolerability of oral amoxicillin in pregnant women with active syphilis, Japan, 2010-2018","volume":"26","author":"Nishijima","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-04980-1","article-title":"Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra)","volume":"20","author":"Taylor","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib51","article-title":"Linezolid against penicillin-sensitive and -resistant pneumococci in therabbit meningitis model","author":"Cottagnoud","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib53","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib54","first-page":"465","article-title":"Global status of Azithromycin and Erythromycin Resistance Rates in Neisseria gonorrhoeae: a systematic review and meta-analysis","volume":"95","author":"Lu","year":"2022","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.lanepe.2023.100737_bib55","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections","volume":"20","author":"Moran","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib56","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/cid\/ciac371","article-title":"Resistance-guided therapy for Neisseria gonorrhoeae","volume":"75","author":"Allan-Blitz","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib57","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/infdis\/jiy551","article-title":"Azithromycin susceptibility among Neisseria gonorrhoeae isolates and seasonal macrolide use","volume":"219","author":"Olesen","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib58","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.lanepe.2023.100743","article-title":"Management of asymptomatic sexually transmitted infections in Europe: towards a differentiated, evidence-based approach.","volume":"34","author":"Kenyon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2023.100737_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1473-3099(20)30734-9","article-title":"Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study","volume":"21","author":"Morris","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/cis1022","article-title":"Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial","volume":"56","author":"Manhart","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib61","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/599033","article-title":"A\u00a0randomized comparison of azithromycin and doxycycline for the treatment of mycoplasma genitalium-positive urethritis in men","volume":"48","author":"Mena","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/ciq074","article-title":"Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens\u2013a randomized clinical trial","volume":"52","author":"Schwebke","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib63","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cid\/ciw719","article-title":"Azithromycin 1.5 g over 5 days compared to 1 g single dose in urethral mycoplasma genitalium: impact on treatment outcome and resistance","volume":"64","author":"Read","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/sextrans-2016-053060","article-title":"Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis","volume":"94","author":"Horner","year":"2018","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib65","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/cid\/civ644","article-title":"The efficacy of azithromycin for the treatment of genital mycoplasma genitalium: a systematic review and meta-analysis","volume":"61","author":"Lau","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib66","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid1207.051558","article-title":"Azithromycin failure in Mycoplasma genitalium urethritis","volume":"12","author":"Bradshaw","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib67","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0956462416688562","article-title":"Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection","volume":"28","author":"Li","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.lanepe.2023.100737_bib68","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dkac281","article-title":"Challenges of in\u00a0vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium","volume":"77","author":"Pitt","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib69","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1086\/593188","article-title":"Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance","volume":"47","author":"Jensen","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib70","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/jac\/dks263","article-title":"Detection of macrolide resistance in Mycoplasma genitalium in France.","volume":"67","author":"Chrisment","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12879-015-0781-7","article-title":"Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin.","volume":"15","author":"Guschin","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00278-22","article-title":"parC variants in Mycoplasma genitalium: trends over time and association with moxifloxacin failure","volume":"66","author":"Murray","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib73","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(21)00629-0","article-title":"Individualised treatment of Mycoplasma genitalium infection\u2014incorporation of fluoroquinolone resistance testing into clinical care","volume":"22","author":"Sweeney","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib74","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/cid\/ciab1058","article-title":"Combination therapy for mycoplasma genitalium, and new insights into the utility of parC mutant detection to improve cure","volume":"75","author":"Vodstrcil","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198355","article-title":"Mutations in parc and gyra of moxifloxacin-resistant and susceptible mycoplasma genitalium strains","volume":"13","author":"Hamasuna","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2023.100737_bib76","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib77","series-title":"Evolving antimicrobial resistance in Mycoplasma genitalium: an updated global systematic review and meta-analysis. Late breaker abstract","author":"Chua","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100737_bib78","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of mycoplasma genitalium infections: a prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib79","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","article-title":"Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability","volume":"71","author":"Durukan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115062","article-title":"Clinical evaluation of the ResistancePlus MG FleXible test on the GeneXpert Infinity-48 s instrument: a near-patient assay for simultaneous detection of Mycoplasma genitalium and macrolide resistance","volume":"97","author":"Fern\u00e1ndez-Huerta","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib81","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1128\/JCM.01897-19","article-title":"Evaluation of the ResistancePlus MG FleXible cartridge for near-point-of-care testing of Mycoplasma genitalium and associated macrolide resistance mutations","volume":"58","author":"Sweeney","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.lanepe.2023.100737_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00020-21","article-title":"Performance of three commercial molecular diagnostic assays for the simultaneous detection of Mycoplasma genitalium and macrolide resistance","volume":"59","author":"Le Roy","year":"2021","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.lanepe.2023.100737_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01135-22","article-title":"Clinical performance of three commercial molecular diagnostic assays for the detection of fluoroquinolone resistance-associated mutations in Mycoplasma genitalium","volume":"60","author":"Gardette","year":"2022","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.lanepe.2023.100737_bib84","series-title":"Efficacy of minocycline for the treatment of macrolide resistant Mycoplasma genitalium. Late breaker abstract. STI and HIV world congress","author":"Clarke","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100737_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06910-1","article-title":"Evaluation of treatment with two weeks of doxycycline on macrolide-resistant strains of Mycoplasma genitalium: a retrospective observational study","volume":"21","author":"Goss\u00e9","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib86","series-title":"Effectiveness of Lefamulin for Mycoplasma genitalium Treatment Failures in Australia and the United States (US). Late breaker abstract STI and HIV world congress","author":"Manhart","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100737_bib87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/OLQ.0000000000001092","article-title":"Could intensive screening for gonorrhea\/Chlamydia in preexposure prophylaxis cohorts select for resistance? Historical lessons from a mass treatment campaign in Greenland","volume":"47","author":"Kenyon","year":"2020","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib88","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jdv.16946","article-title":"2020 European guideline on the management of syphilis","volume":"35","author":"Janier","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.lanepe.2023.100737_bib89","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/652239","article-title":"A\u00a0Phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis","volume":"201","author":"Hook","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib90","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMoa044284","article-title":"Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis","volume":"353","author":"Riedner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2023.100737_bib91","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/cid\/ciu888","article-title":"A\u00a0single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis","volume":"60","author":"Ganesan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib92","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/cid\/ciw862","article-title":"Single dose versus 3 doses of intramuscular benzathine penicillin for early syphilis in HIV: a randomized clinical trial","volume":"64","author":"Andrade","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002473","article-title":"Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: an evaluation from multi-country surveys and stakeholder interviews","volume":"14","author":"Nurse-Findlay","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.lanepe.2023.100737_bib94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/sextrans-2019-054380","article-title":"Erroneous treatment of syphilis with benzyl penicillin in an era with benzathine benzylpenicillin shortages","volume":"96","author":"Nieuwenburg","year":"2020","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib95","author":"World Health Organization"},{"key":"10.1016\/j.lanepe.2023.100737_bib96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(23)01665-3","article-title":"Syphilis rates soar in the USA amid penicillin shortage.","volume":"402","author":"Nelson","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.lanepe.2023.100737_bib97","first-page":"1374","article-title":"Failure of benzathine penicillin in a case of seronegative secondary syphilis in a patient with acquired immunodeficiency syndrome: case report and review of the literature","volume":"137","author":"Fowler","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lanepe.2023.100737_bib98","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM199707313370504","article-title":"A\u00a0randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection","volume":"337","author":"Rolfs","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2023.100737_bib99","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1346-8138.1993.tb01314.x","article-title":"Relapsing syphilis","volume":"20","author":"Yoon","year":"1993","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.lanepe.2023.100737_bib100","doi-asserted-by":"crossref","first-page":"14917","DOI":"10.1074\/jbc.M400666200","article-title":"A\u00a0novel \u03b2-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin","volume":"279","author":"Cha","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.lanepe.2023.100737_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103281","article-title":"Efficacy of linezolid on Treponema pallidum, the syphilis agent: a preclinical study","volume":"65","author":"Haynes","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.lanepe.2023.100737_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00979-20","article-title":"In\u00a0vitro susceptibility of Treponema pallidum subsp. pallidum to doxycycline","volume":"64","author":"Edmondson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00219-7","article-title":"In vitro antimicrobial susceptibility of Treponema pallidum subsp. pallidum","author":"Tantalo","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanepe.2023.100737_bib104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa040216","article-title":"Macrolide resistance in Treponema pallidum in the United States and Ireland","volume":"351","author":"Lukehart","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2023.100737_bib105","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/fmb-2021-0037","article-title":"Multilocus sequence typing of Treponema pallidum subsp. pallidum in Barcelona","volume":"16","author":"Fern\u00e1ndez-Naval","year":"2021","journal-title":"Future Microbiol"},{"key":"10.1016\/j.lanepe.2023.100737_bib106","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1469-0691.12098","article-title":"High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.lanepe.2023.100737_bib107","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/OLQ.0b013e31826f36de","article-title":"Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009","volume":"39","author":"Su","year":"2012","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib108","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2666-5247(22)00035-0","article-title":"Characterisation of Treponema pallidum lineages within the contemporary syphilis outbreak in Australia: a genomic epidemiological analysis","volume":"3","author":"Taouk","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanepe.2023.100737_bib109","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/JCM.01292-14","article-title":"Molecular typing of Treponema pallidum in the Czech republic during 2011 to 2013: increased prevalence of identified genotypes and of isolates with macrolide resistance","volume":"52","author":"Grillov\u00e1","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.lanepe.2023.100737_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11216-7","article-title":"Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineages","volume":"10","author":"Beale","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanepe.2023.100737_bib111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.medmal.2011.10.003","article-title":"Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis","volume":"42","author":"Psomas","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.lanepe.2023.100737_bib112","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/cid\/cix611","article-title":"A\u00a0multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China","volume":"65","author":"Cao","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib113","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1473-3099(20)30857-4","article-title":"Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study","volume":"21","author":"Bettuzzi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib114","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06769-w","article-title":"Ceftriaxone compared with penicillin G for the treatment of neurosyphilis: study protocol for a multicenter randomized controlled trial","volume":"23","author":"Du","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.lanepe.2023.100737_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109813","article-title":"Comparison of serological response to doxycycline versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients: a multi-center observational study","volume":"9","author":"Tsai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2023.100737_bib116","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1086\/500406","article-title":"Doxycycline compared with benzathine penicillin for the treatment of early syphilis","volume":"42","author":"Ghanem","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib117","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01092-16","article-title":"Efficacy of doxycycline in the treatment of syphilis","volume":"61","author":"Dai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib118","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/jac\/dkab100","article-title":"Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis","volume":"76","author":"Girometti","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib119","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/OLQ.0000000000000445","article-title":"Molecular subtyping and surveillance of resistance genes in Treponema pallidum DNA from patients with secondary and latent syphilis in Hunan, China","volume":"43","author":"Xiao","year":"2016","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.lanepe.2023.100737_bib120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.01095-09","article-title":"Global challenge of antibiotic-resistant Treponema pallidum","volume":"54","author":"Stamm","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanepe.2023.100737_bib121","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.lanepe.2023.100738","article-title":"Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe.","volume":"34","author":"G\u00f6kengin","year":"2023","journal-title":"Lancet Reg Health Eur."},{"key":"10.1016\/j.lanepe.2023.100737_bib122","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/cid\/ciab187","article-title":"Clinical efficacy of cefixime for\u00a0the treatment of early syphilis","volume":"73","author":"Stafylis","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:57:25Z","timestamp":1763009845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776223001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":120,"alternative-id":["S2666776223001564"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100737","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100738","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100760","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100742","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100766","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100743","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100737"}}